Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Urology
|
September 11, 2001
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria
G Bartsch, W Horninger, H Klocker, et al.
Urology
|
December 1, 1996
Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening
A Reissigl, H Klocker, J Pointner, et al.
The Journal of Urology
|
June 15, 2007
Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score
M Mitterberger, G M Pinggera, W Horninger, et al.
Diabetologia
|
March 10, 2005
Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia
A P Berger, M Deibl, E J Halpern, et al.
Prostate Cancer and Prostatic Diseases
|
February 6, 2013
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer
G Schaefer, J-M Mosquera, R Ramoner, et al.
Prostate Cancer and Prostatic Diseases
|
March 22, 2017
ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study
I Heidegger, H Klocker, R Pichler, et al.
Der Radiologe
|
June 27, 2003
[The value of ultrasound (US) in the diagnosis of prostate cancer]
F Frauscher, A Klauser, A P Berger, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening
N Mühlberger, E A M Heijnsdijk, C Kurzthaler, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
August 20, 2021
Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer-a valid option for cisplatin-unfit patients?
C R Arnold, A K Lindner, G Schachtner, et al.
The Journal of Urology
|
March 29, 2000
Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate
R Ischia, A Hobisch, R Bauer, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Urology
|
September 11, 2001
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria
G Bartsch, W Horninger, H Klocker, et al.
Urology
|
December 1, 1996
Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening
A Reissigl, H Klocker, J Pointner, et al.
The Journal of Urology
|
June 15, 2007
Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score
M Mitterberger, G M Pinggera, W Horninger, et al.
Diabetologia
|
March 10, 2005
Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia
A P Berger, M Deibl, E J Halpern, et al.
Prostate Cancer and Prostatic Diseases
|
February 6, 2013
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer
G Schaefer, J-M Mosquera, R Ramoner, et al.
Prostate Cancer and Prostatic Diseases
|
March 22, 2017
ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study
I Heidegger, H Klocker, R Pichler, et al.
Der Radiologe
|
June 27, 2003
[The value of ultrasound (US) in the diagnosis of prostate cancer]
F Frauscher, A Klauser, A P Berger, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening
N Mühlberger, E A M Heijnsdijk, C Kurzthaler, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
August 20, 2021
Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer-a valid option for cisplatin-unfit patients?
C R Arnold, A K Lindner, G Schachtner, et al.
The Journal of Urology
|
March 29, 2000
Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate
R Ischia, A Hobisch, R Bauer, et al.
Page
of 5